ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
ALNYLAM PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$233.29+1.46 (+0.63%)
Close on Oct 19, 2026
- Market cap
- $32.26B
- P/E (TTM)
- 43.4
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
81.8%−3.2 pts over 5 years
Operating margin
13.5%+181.6 pts over 5 years
Net margin
8.4%+182.6 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +65.2% | +53.0% | +49.8% | – | |
| Gross profit | +56.4% | +50.1% | +48.6% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -37.5% | -69.9% | 73.3% | |
| Return on assets | -31.0% | -29.6% | 6.8% | |
| Current ratio | 5.10 | 4.47 | 2.76 | |
| Interest coverage | – | -9.8× | 2.0× | |
| Inventory turnover | – | 1.1× | 8.4× | |
| Capex to revenue | 136.9% | 14.3% | 1.6% | |
| Diluted shares | 86M | 115M | 135M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Alnylam Pharmaceuticals generated $1.82B from operations and spent $303.62M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$1.82B
Used
$303.62M
Capital expenditure$303.62M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin8.4%
×Asset turnover0.81×
×Equity multiplier10.75×
=Return on equity, FY202573.3%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 8.4% | 0.81× | 10.75× | 73.3% |
| FY2024 | -12.4% | 0.56× | -52.55× | 362.3% |
| FY2023 | -24.1% | 0.50× | -19.47× | 232.4% |
| FY2022 | -109.0% | 0.29× | 16.72× | -526.1% |
| FY2021 | -101.0% | 0.24× | 4.39× | -106.3% |
| FY2020 | -174.1% | 0.17× | 2.36× | -69.9% |
| FY2019 | -403.2% | 0.11× | 1.45× | -64.7% |
| FY2018 | -1016.6% | 0.04× | 1.16× | -49.6% |
| FY2017 | -545.9% | 0.06× | 1.21× | -36.5% |
| FY2016 | -869.6% | 0.04× | 1.21× | -37.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$313.75M
- Cash generatingOperating cash flow above zero$524.08M
- Return on assets improvedROA up on the prior year-7.3% → 7.4%
- Earnings backed by cashOperating cash flow above net income$524.08M vs $313.75M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.78 → 2.76
- No dilutionShare count did not rise128M → 135M
- Gross margin improvedGross margin up on the prior year86.37% → 81.77%
- More efficientAsset turnover rose0.59 → 0.88